CCL2 and COVID-19: Patients with COVID-19 have shown to have increased levels of IL-1B, IFN-γ, IP-10, and monocyte chemoattractant protein 1 (MCP-1) that are part Th1 immune response responsible the activation of specific immunity, but also higher levels of IL-4 and IL-10 that represent the part of the TH2 immune response that shows the anti-inflammatory effects (Ye et al., 2020).